Hypertension and sudden cardiac death

American Journal of Hypertension

Volumn 12, Issue 12 SUPPL. 1, 1999, Pages 181S-188S

  Messerli, Franz H ^a,b  

^a OCHSNER MEDICAL CENTER   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Drug therapy; Hypertensive heart disease; Sudden death; Ventricular ectopy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; PRAZOSIN; RENIN;

ADRENERGIC SYSTEM; CLINICAL TRIAL; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SUDDEN DEATH;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 0033395402     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00106-5     Document Type: Article

References (80)

1. Kannel WB: Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983;75(suppl 3A):4-11.
2. Koren MJ, Devereux RB, Casale PN, et al: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
3. Messerli FH, Ventura HO, Elizardi DJ, et al: Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984;77:18-22.
4. Messerli FH, Soria F: Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Med 1992;93:21S-26S.
5. Messerli FH, Nunez BD, Nunez MM, et al: Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989;149:1263-1267.
6. Levy D, Anderson KM, Savage DD, et al: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13.
7. McLenachan JM, Henderson E, Morris KI, Dargie HJ: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787-792.
8. Bikkina M, Larson MG, Levy D: Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993;22:1111-1116.
9. Messerli FH, Glade LB, Elizardi DG, et al: Cardiac rhythm, arterial pressure, and urinary catecholamines in hypertension with and without left ventricular hypertrophy (abstract). Am J Cardiol 1981;47:480.
10. Loaldi A, Pepi M, Agostoni PG, et al: Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring: effects of load manipulation with atenolol, verapamil, and nifedipine. Br Heart J 1983;50:118-126.
11. Aronow WS, Epstein S, Schwartz KS, Koenigsberg M: Correlation of complex ventricular arrhythmias detected by ambulatory electrocardiographic monitoring with echocardiographic left ventricular hypertrophy in persons older than 62 years in a long-term health care facility. Am J Cardiol 1987;60:730-732.
12. Levy D, Anderson KM, Savage DD, et al: Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-565.
13. Lavie CJ Jr, Nunez BD, Garavaglia GE, Messerli FH: Hypertensive concentric left ventricular hypertrophy: when is ventricular ectopic activity increased? South Med J 1988;81:696-700.
14. Papademetriou V, Notargiacomo A, Heine D, et al: Ventricular arrhythmias in patients with essential hypertension (abstract). J Am Coll Cardiol 1989;13:105A.
15. Szlachcic J, London M, Tubau JF, et al: Incidence of serious ventricular arrhythmias during surgery in hypertensives with left ventricular hypertrophy (abstract). J Am Coll Cardiol 1989;13:105A.
16. James MA, Jones JV: Ventricular arrhythmia in untreated newly presenting hypertensive patients compared with a matched normal population. J Hypertens 1989;7:409-415.
17. Ferrara N, Furgi G, Longobardi G, et al: Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. J Hum Hypertens 1995;9:581-587.
18. Siegel D, Cheitlin MD, Black DM, et al: Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol 1990;65:742-747.
19. Galinier M, Fermond B, Lambert V, et al: When is a search for ventricular arrhythmias necessary in hypertensive patients (abstract). J Hypertens 1991;9:874-875.
20. Melina D, Colivicchi F, Guerrera G, Santoliquido A: Rhythm of disturbances in essential hypertension. J Hum Hypertens 1991;5:233.
21. Ghali JK, Kadakia S, Cooper RS, Liao YL: Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991;17:1277-1282.
22. Novo S, Barbagallo M, Abrignani MG, et al: Cardiac arrhythmias as correlated with the circadian rhythm of arterial pressure in hypertensive subjects with and without left ventricular hypertrophy. Eur J Clin Pharmacol 1990;39(suppl 1):S49-S51.
23. Messerli FH , Grodzicki T: Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992;13(suppl D):66-69.
24. Nunez BD, Lavie CJ, Messerli FH, et al: Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 1994;74:585-589.
25. Vardas PE, Simandirakis EN, Parthenakis FI, et al: Study of late potentials and ventricular arrhythmias in hypertensive patients with normal electrocardiograms. Pacing Clin Electrophysiol 1994;4:577-584.
26. Schillaci G, Verdecchia P, Borgioni C, et al: Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. Hypertension 1996;2:284-289.
27. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-1022.
28. O'Gorman DJ, Sheridan DJ: Abnormalities of the coronary circulation associated with left ventricular hypertrophy. Clin Sci 1991;81:703-713.
29. Houghton JL, Prisant LM, Carr AA, et al: Relationship of left ventricular mass to impairment of coronary vasodilator reserve in hypertensive heart disease. Am Heart J 1991;121:1107-1112.
30. Lucarini AR, Picano E, Salvetti A: Coronary microvascular disease in hypertensives. Clin Exp Hypertens 1992;A14:55-66.
31. Houghton JL, Carr AA, Prisant LM, et al: Morphologic, hemodynamic and coronary perfusion characteristics in severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia. Am J Cardiol 1992;69:219-224.
32. Harrison DG, Marcus ML, Dellsperger KC, et al: Pathophysiology of myocardial perfusion in hypertension. Circulation 1991;83(suppl III):III-14-III-18.
33. Burke AP, Farb A, Liang YH, et al: Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996;94:3138-3145.
34. Burke AP, Farb A, Malcom GT, et al: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-1282.
35. Levy D, Anderson KM, Plehn J, et al: Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol 1987;59:836-840.
36. Palatini P, Maraglino G, Accurso V, et al: Impaired left ventricular filling in hypertensive left ventricular hypertrophy as a marker of the presence of an arrhythmogenic substrate. Br Heart J 1995;73:258-262.
37. Polese A, De Cesare N, Fabbiocchi F, et al: Coronary autoregulation in hypertension: correlation with left ventricular mass (abstract). J Am Coll Cardiol 1990;15:111A.
38. Nunez BD, Messerli FH, Garavaglia GE, Schmieder RE: Exaggerated atrial and ventricular excitability in hypertensive patients with isolated septal hypertrophy (ISH) (abstract). J Am Coll Cardiol 1987;9:225A.
39. Toyoshima H, Park Y-D, Ishikawa Y, et al: Effects of ventricular hypertrophy on conduction velocity of activation front in the ventricular myocardium. Am J Cardiol 1982;49:1938-1945.
40. Leyton RA, Sonnenblick EH: The ultrastructure of the failing heart. Am J Med Sci 1969;258:304-327.
41. Sideris DA, Kontoyannis DA, Michails L, et al: Acute changes in blood pressure as a cause of cardiac arrhythmias. Eur Heart J 1987;8:45-52.
42. Sideris DA, Toumanidis ST, Kostis EB, et al: Arrhythmogenic effect of high blood pressure: some observation on its mechanism. Cardiovasc Res 1989;23:983-992.
43. James MA, Jones JV: Systolic wall stress and ventricular arrhythmia: the role of acute change in blood pressure in the isolated working rat heart. Clin Sci 1990;79:499-504.
44. Bustamante JO, Ruknudin A, Sachs F: Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol 1991;17(suppl 2):S110-S113.
45. Schwartz P, La Rovere MT, Vanoli E: Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85(suppl I): I-77-I-91.
46. Anderson JL, Rodier HE, Green LS: Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-1202.
47. Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17.
48. Amerena J, Julius S: The role of the autonomic nervous system in hypertension. Hypertens Res 1995;18:99-110.
49. Paul M, Ganten D: The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol 1992;19(suppl 5):S51-S58.
50. Harrap SB, Mitchell GA, Casley DJ, et al: Angiotensin II, sodium, and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension 1993;21:50-55.
51. Kowey PR, Friechling TD, Sewter J, et al: Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation 1991;83:2067-2075.
52. Clementy J, Coste P, Dallocchio M, Bricaud H: Data of programmed ventricular stimulation in left ventricular hypertrophy of hypertensive origin [in French]. Ann Cardiol Angeiol (Paris) 1989;38:297-303.
53. Vester EG, Kuhls S, Ochiulet-Vester J, et al: Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992;13(suppl D):70-81.
54. Singh JP, Sleight P, Kardos A, Hart G: QT interval dynamics and heart rate variability preceding a case of cardiac arrest. Heart 1997;77:375-377.
55. Aronow WS, Epstein S, Koenigsberg M, Schwartz KS: Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988;62:1124-1125.
56. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
57. Böhlen L, Weidmann PL, de Courten M, et al: Antihypertensive drug effects on left ventricular hypertrophy: meta-analysis considering duration of treatment (abstract). J Hypertens 1994;12(suppl 3):S140.
58. Cruickshank JM, Lewis J, Moore V, Dodd C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
59. Schmieder RE, Martus P, Klingbell A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
60. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-569.
61. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
62. Dzau VJ: Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart, in Grobecker H, Heusch G, Strauer BE (eds): Angiotensin and the Heart. Springer-Verlag, New York, 1993, pp 1-14.
63. Gottdiener JS, Reda DJ, Massie BM, et al: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-2014.
64. Mizuno K, Tani M, Hashimoto S, et al: Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992;51:367-374.
65. Nunez E, Hosoya K, Susic D, Frohlich ED: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997;29:519-524.
66. Ledingham JM, Laverty R: Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996;23(6-7):576-578.
67. de Simone G, Devereux RB, Camargo MJ, et al: Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996;9:216-222.
68. Kohya T, Yokoshiki H, Tohse N, et al: Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995;76:892-899.
69. Bruckschlegel G, Holmer SR, Jandeleit K, et al: Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 1995;25:250-259.
70. Himmelmann A, Svensson A, Bergbrant A, Hansson L: Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996;10:729-734.
71. Cheung B: Increased left-ventricular mass after losartan treatment. Lancet 1997;349:1743-1744.
72. Thürmann PA, Kenedi P, Schmidt A, et al: Valsartan, a novel angiotensin II receptor antagonist, reduces left ventricular hypertrophy in patients with essential hypertension (abstract). Presented at the 13th World Congress of Cardiology, April 26-30, 1998, Rio de Janeiro.
73. Kahan T, Malmqvist M, Edner M, et al: Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade (abstract). J Am Coll Cardiol 1998;31(suppl A):212A.
74. Dahlof B, Devereux R, de Faire U, et al: The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-713.
75. González-Fernández RA, Rivera M, Rodriguez PJ, et al: Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens 1993;6:308-313.
76. Siscovick DS, Raghunathan TE, Psaty BM, et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857.
77. Caralis PV, Materson BJ, Perez-Stable E: Potassium and diuretic-induced ventricular arrhythmias in ambulatory hypertensive patients. Miner Electrolyte Metab 1984;10:148-154.
78. Hollifield JW: Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med 1984;77:28-32.
79. Levy D, Salomon M, D'Agostino RB, et al: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-1793.
80. Yurenev AP, Dyakonova HG, Novikov ID, et al: Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5:182S-189S.